Nerima-ku, Japan Clinical Trials

A listing of Nerima-ku, Japan clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 581 clinical trials
featured
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

www.MyelofibrosisResearch.com This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

Nippon Medical School Hospital /ID# 222692
 (6.1 away) Contact site
  • 251 views
  • 29 Apr, 2021
  • +134 other locations
featured
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called platelets, which increases …

Nippon Medical School Hospital /ID# 221674
 (6.1 away) Contact site
  • 32 views
  • 29 Apr, 2021
  • +148 other locations
featured
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to assess …

Tokyo Medical University Hospital /ID# 221540
 (3.9 away) Contact site
  • 164 views
  • 29 Apr, 2021
  • +224 other locations
featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.  

cancer
primary cancer
metastatic cancer
FGFR2
Keio University Hospital
 (5.2 away) Contact site
  • 154 views
  • 14 Dec, 2020
  • +154 other locations
featured
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received …

metastatic urothelial carcinoma
bladder carcinoma
urothelial carcinoma
bladder cancer
Keio University Hospital
 (5.2 away) Contact site
  • 22 views
  • 14 Dec, 2020
  • +63 other locations
featured
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.  

FGFR1
FGFR3
primary cancer
metastasis
primary tumor
Keio University Hospital
 (5.2 away) Contact site
  • 46 views
  • 14 Dec, 2020
  • +61 other locations
A Study of JNJ-73763989 JNJ-56136379 Nucleos(t)Ide Analogs and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

The purpose of this study is to evaluate the efficacy in terms of hepatitis B surface antigen (HBsAg) levels of the study intervention (that is, JNJ-73763989 + JNJ-56136379 + nucleos[t]ide analog [NA] and pegylated interferon alpha-2a [PegIFN-alpha2a].

Tokyo Medical and Dental University Medical Hospital
 (6.8 away) Contact site
  • 0 views
  • 21 Apr, 2021
  • +10 other locations
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

The main aim of the study is to check for side effects of TAK-755. Participants will either receive TAK-755 every week or every other week to prevent bleeds (prophylactic arm) or they will receive TAK-755 to treat an acute bleed (on-demand arm). Participants in the prophylactic arm will receive treatment …

Medical Hospital,Tokyo Medical and Dental University
 (6.8 away) Contact site
  • 0 views
  • 16 May, 2021
  • +21 other locations
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. This study evaluates how safe and effective ABBV-154 is in participants treated for moderately to severely active RA. Adverse events and change in the disease activity will be assessed. ABBV-154 is …

rheumatism
antirheumatics
methotrexate
stiffness
National Hospital Organization Tokyo Medical Center /ID# 228720
 (7.6 away) Contact site
  • 0 views
  • 17 Jun, 2021
  • +255 other locations
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants with eosinophilic esophagitis (EoE). The study will incorporate a 24-week Induction Phase followed by a 24-week Maintenance Phase. Participants will be …

Center Hospital of the National Center for Global Health and Medicine
 (4.3 away) Contact site
  • 0 views
  • 02 May, 2021
  • +200 other locations